Project Grant R01EY036458
Award Date 9/1/25
Completion Date 5/31/28
Dollars Obligated $644K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Eye Institute (NEI) awarded a $451,000 Project Grant under the Vision Research federal grant program (CFDA 93.867) to The Regents of the University of California, San Francisco (UCSF) to conduct a multimodal characterization of a novel inherited mouse model of glaucoma. The research aims to evaluate structural and functional changes in the mouse model, including axonal degeneration, retinal ganglion cell loss, dendritic changes, and neuroinflammatory responses. It will also identify...
- This Project Grant award for $679,159 from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research on in vivo epigenetic reprogramming of retinal ganglion cells (RGCs) in aging mice with glaucoma. The research aims to identify new therapeutic targets for glaucoma that can protect and rejuvenate RGCs, which are specifically targeted and damaged in this disease leading to vision loss. The 4-year project, awarded to The Schepens Eye...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding to Human Cell Co, a for-profit biotechnology research company, to develop a combination therapy for glaucoma. The award, totaling $360,897, will support research to determine if topical application of a nerve growth factor (NGF) mutein (HC201) in combination with oral nicotinamide (NAM) supplementation can more effectively improve retinal ganglion cell function compared to either treatment...
- The National Eye Institute (NEI), under the Department of Health and Human Services, has awarded a $695,050 Project Grant to The Leland Stanford Junior University (Stanford University) to investigate the role of cholinergic dysfunction in the pathogenesis of glaucoma. The grant, funded through the NEI's Vision Research program (CFDA 93.867), aims to leverage advanced magnetic resonance imaging (MRI) and spectroscopy (MRS) techniques to identify and quantify cholinergic changes in the visual...
- This $617,201 Project Grant awarded by the National Eye Institute's Vision Research program aims to leverage innovative tools from engineering, AI, and advanced optical coherence tomography (OCT) imaging to directly observe and unveil the specific mechanical insults to retinal ganglion cell axons that contribute to vision loss progression in glaucoma patients. The research team from Emory University intends to monitor glaucoma patients longitudinally to identify where these axonal insults,...
- This Project Grant award of $423,767 from the National Eye Institute (CFDA 93.867 - Vision Research) supports research at the University of California, Davis focused on understanding the role of myeloid cells in glaucoma-related axonal degeneration. The project aims to determine whether NAD+-based interventions can protect retinal ganglion cell axons in a glaucoma-relevant model of axon injury, and to characterize the associated immune response. The research will leverage novel axon injury...
- This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), provides $502,677 to The Leland Stanford Junior University (Stanford University) to develop chemical modulators of endoplasmic reticulum (ER) stress as neuroprotective treatments for glaucoma. The research aims to optimize promising ER stress modulator compounds identified through high-throughput screening, evaluate their efficacy in mouse models of glaucoma, and...
- The National Eye Institute (NEI), under the federal Vision Research grant program (CFDA 93.867), awarded a $300,016 project grant to Fannin Partners LLC, a Houston-based biomedical research company, to develop SCG3 raptamers as a novel targeted therapy for wet age-related macular degeneration (AMD). Wet AMD is a leading cause of vision loss, affecting over 1.25 million individuals in the United States. The project aims to create an aptamer-based treatment that targets secretogranin III (SCG3), a...
- This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $127,861 to The Regents of the University of California, Berkeley to conduct research on the role and regulation of a distinct optic nerve microglia population in glaucomatous neuropathy. The research aims to elucidate how the lipoxin LXB4 regulates disease-associated microglia (DAM) in the optic nerve during ocular hypertension, a key mechanism in the neuroprotective effects of LXB4 against...
- This $417,162 Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) supports research on using optical techniques to detect early signs of glaucoma, the leading cause of irreversible blindness worldwide. The University of Houston System, the grantee, will conduct research to determine if changes in the birefringence (optical properties) of the lamina cribrosa and posterior eye structures can serve as sensitive early indicators of glaucoma before structural damage...